Jun. 28 at 6:09 PM
$EDSA This company as I've said a million times is a black box. As investors all we as can ask as their internal workload might be a little light until the manufacturing campaign is complete, that they are working studiously on the EB07 IND and also working to continue partnership talks for EB01. EB07 is particularly important in my view. While they don't have the capital to initiate a trial, an approved IND would go a long way in positioning paridiprubart as a multi indication drug, ergo commanding a higher premium. Obviously right now we are in no man's land essentially waiting the EB06 IND and updates on the BARDA trial as they become available so there's really not much to get excited about. Still praying they are actively working on partnering up. I believe that's the best way to create some value.
